About Foresee Pharmaceuticals
Foresee Pharmaceuticals is a company based in Taipei (Taiwan) founded in 2011.. Foresee Pharmaceuticals has raised $32.5 million across 4 funding rounds from investors including CDIB Capital Group. Foresee Pharmaceuticals operates in a competitive market with competitors including Insulet, Flexion Therapeutics, Lyra Therapeutics, Cara Therapeutics and Eliem Therapeutics, among others.
- Headquarter Taipei, Taiwan
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
- Legal Name Foresee Pharmaceuticals Co., Ltd.
-
Annual Revenue
$0 (USD)114.67as on Dec 31, 2024
-
Net Profit
$0 (USD)-4.32as on Dec 31, 2024
-
EBITDA
$0 (USD)-6.99as on Dec 31, 2024
-
Total Equity Funding
$32.5 M (USD)
in 4 rounds
-
Latest Funding Round
- Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Foresee Pharmaceuticals
Foresee Pharmaceuticals is a publicly listed company on the TPEX with ticker symbol 6576 in Taiwan, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Funding Insights of Foresee Pharmaceuticals
Foresee Pharmaceuticals has successfully raised a total of $32.5M across 4 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Last Round
- First Round First Round
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2020 | Amount | Post-IPO - Foresee Pharmaceuticals | Valuation |
investors |
|
| Feb, 2016 | Amount | Series D - Foresee Pharmaceuticals | Valuation |
investors |
|
| Oct, 2014 | Amount | Series C - Foresee Pharmaceuticals | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Foresee Pharmaceuticals
Foresee Pharmaceuticals has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include CDIB Capital Group. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Sector-agnostic investments are made in early-stage Asia Pacific startups.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Foresee Pharmaceuticals
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Foresee Pharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Foresee Pharmaceuticals Comparisons
Competitors of Foresee Pharmaceuticals
Foresee Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insulet, Flexion Therapeutics, Lyra Therapeutics, Cara Therapeutics and Eliem Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Wearable insulin infusion systems are developed for diabetes patients.
|
|
| domain | founded_year | HQ Location |
Developer of therapies for the treatment of musculoskeletal disorders
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for ENT diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics for pain relief and inflammatory diseases
|
|
| domain | founded_year | HQ Location |
Develops antibody-based treatments for autoimmune and inflammatory disorders.
|
|
| domain | founded_year | HQ Location |
Therapies for pain and addiction treatment are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Foresee Pharmaceuticals
Frequently Asked Questions about Foresee Pharmaceuticals
When was Foresee Pharmaceuticals founded?
Foresee Pharmaceuticals was founded in 2011 and raised its 1st funding round 3 years after it was founded.
Where is Foresee Pharmaceuticals located?
Foresee Pharmaceuticals is headquartered in Taipei, Taiwan.
Is Foresee Pharmaceuticals a funded company?
Foresee Pharmaceuticals is a funded company, having raised a total of $32.5M across 4 funding rounds to date. The company's 1st funding round was a Series C of $18M, raised on Jun 01, 2014.
What does Foresee Pharmaceuticals do?
Foresee Pharmaceuticals develops injectables and NCEs for cancer, endocrine disorders, and inflammatory diseases. Its stabilized injectable formulation platform is primarily a controlled release drug delivery platform for small molecules, peptides, and other bioactive. Its lead candidate is in phase III trials for prostate cancer, and another candidate in phase II trials for COPD and asthma. In addition, it has other candidates for acromegaly, opioid dependence, diabetic retinopathy and alport syndrome in preclinical studies. Its pipeline candidates are FP-001 (Leuprolide) for prostate cancer, FP-004 (Buprenorphine) for opioid dependence, and FP-011 (Goserelin) for the breast cancer among others.
Who are the top competitors of Foresee Pharmaceuticals?
Foresee Pharmaceuticals's top competitors include Insulet, Flexion Therapeutics and Lyra Therapeutics.
Is Foresee Pharmaceuticals publicly traded?
Yes, Foresee Pharmaceuticals is publicly traded on TPEX under the ticker symbol 6576.
Who are Foresee Pharmaceuticals's investors?
Foresee Pharmaceuticals has 1 investor. Key investors include CDIB Capital Group.
What is Foresee Pharmaceuticals's ticker symbol?
The ticker symbol of Foresee Pharmaceuticals is 6576 on TPEX.